AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
gabapentin enacarbil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| gabamimetic agents | 4177 | 478296-72-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Gabapentin enacarbil is a prodrug of gabapentin and, accordingly, its therapeutic effects in restless legs syndrome and postherpetic neuralgia are attributable to gabapentin. In animal models of analgesia, gabapentin prevents allodynia (pain-related behavior in response to a normally innocuous stimulus) and hyperalgesia (exaggerated response to painful stimuli).
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 0.50 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
| BA (Bioavailability) | 60 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,IKBKB,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PIM2,PLK1,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,ZAP70 | 43 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,CDK9,GRK2,MAP2K6 | 6 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 6, 2011 | FDA | XENOPORT INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxicity to various agents | 1009.78 | 34.02 | 320 | 1445 | 287526 | 90339156 |
| Completed suicide | 491.79 | 34.02 | 159 | 1606 | 144899 | 90481783 |
| Cardio-respiratory arrest | 179.41 | 34.02 | 61 | 1704 | 63079 | 90563603 |
| Drug abuse | 159.90 | 34.02 | 60 | 1705 | 82287 | 90544395 |
| Accidental overdose | 115.40 | 34.02 | 36 | 1729 | 28237 | 90598445 |
| Myoclonus | 48.37 | 34.02 | 17 | 1748 | 19151 | 90607531 |
| Rib deformity | 36.04 | 34.02 | 6 | 1759 | 274 | 90626408 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxicity to various agents | 661.49 | 48.56 | 265 | 1407 | 228871 | 42390792 |
| Completed suicide | 292.18 | 48.56 | 117 | 1555 | 96348 | 42523315 |
| Drug abuse | 151.40 | 48.56 | 76 | 1596 | 104695 | 42514968 |
| Cardio-respiratory arrest | 100.76 | 48.56 | 48 | 1624 | 58588 | 42561075 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxicity to various agents | 1686.70 | 35.85 | 584 | 2518 | 479971 | 110106226 |
| Completed suicide | 761.28 | 35.85 | 275 | 2827 | 242106 | 110344091 |
| Drug abuse | 321.67 | 35.85 | 136 | 2966 | 177275 | 110408922 |
| Cardio-respiratory arrest | 278.99 | 35.85 | 109 | 2993 | 115727 | 110470470 |
| Accidental overdose | 176.51 | 35.85 | 63 | 3039 | 51771 | 110534426 |
| Myoclonus | 78.92 | 35.85 | 31 | 3071 | 32967 | 110553230 |
| Intentional product misuse | 49.53 | 35.85 | 36 | 3066 | 132868 | 110453329 |
| Bacteroides infection | 38.15 | 35.85 | 10 | 3092 | 2909 | 110583288 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| FDA PE | N0000008486 | Decreased Central Nervous System Disorganized Electrical Activity |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D000927 | Anticonvulsants |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014151 | Anti-Anxiety Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018689 | Sensory System Agents |
| MeSH PA | D018691 | Excitatory Amino Acid Antagonists |
| MeSH PA | D018692 | Antimanic Agents |
| CHEBI has role | CHEBI:35469 | antidepressant |
| CHEBI has role | CHEBI:35474 | anxiolytic drug |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35623 | anticonvulsant |
| CHEBI has role | CHEBI:35703 | xenobiotic |
| CHEBI has role | CHEBI:35705 | immunosuppressive agent |
| CHEBI has role | CHEBI:38215 | calcium channel blocker |
| CHEBI has role | CHEBI:62868 | hepatoprotective agent |
| CHEBI has role | CHEBI:63726 | neuroprotective agent |
| CHEBI has role | CHEBI:64946 | anti-HIV agent |
| CHEBI has role | CHEBI:73336 | vulnerary |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
| CHEBI has role | CHEBI:78298 | environmental contaminant |
| CHEBI has role | CHEBI:50266 | prodrug |
| CHEBI has role | CHEBI:231911 | renoprotective agent |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Postherpetic neuralgia | indication | 2177002 | |
| Restless legs | indication | 32914008 | DOID:0050425 |
| Partial Epilepsy Treatment Adjunct | off-label use | ||
| Suicidal thoughts | contraindication | 6471006 | |
| Depressive disorder | contraindication | 35489007 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.33 | acidic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 300MG | HORIZANT | AZURITY | N022399 | Dec. 13, 2011 | RX | TABLET, EXTENDED RELEASE | ORAL | 8114909 | April 11, 2026 | TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS |
| 600MG | HORIZANT | AZURITY | N022399 | April 6, 2011 | RX | TABLET, EXTENDED RELEASE | ORAL | 8114909 | April 11, 2026 | TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS |
| 300MG | HORIZANT | AZURITY | N022399 | Dec. 13, 2011 | RX | TABLET, EXTENDED RELEASE | ORAL | 8795725 | June 10, 2029 | MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS |
| 300MG | HORIZANT | AZURITY | N022399 | Dec. 13, 2011 | RX | TABLET, EXTENDED RELEASE | ORAL | 8795725 | June 10, 2029 | TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS |
| 600MG | HORIZANT | AZURITY | N022399 | April 6, 2011 | RX | TABLET, EXTENDED RELEASE | ORAL | 8795725 | June 10, 2029 | MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS |
| 600MG | HORIZANT | AZURITY | N022399 | April 6, 2011 | RX | TABLET, EXTENDED RELEASE | ORAL | 8795725 | June 10, 2029 | TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Voltage-dependent calcium channel subunit alpha-2/delta-1 | Ion channel | MODULATOR | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||||
| Voltage-dependent calcium channel subunit alpha-2/delta-2 | Ion channel | MODULATOR | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE |
External reference:
| ID | Source |
|---|---|
| 4030724 | VUID |
| N0000182734 | NUI |
| D09539 | KEGG_DRUG |
| 4020833 | VANDF |
| 4030724 | VANDF |
| C2700226 | UMLSCUI |
| CHEBI:68840 | CHEBI |
| GBN | PDB_CHEM_ID |
| CHEMBL1628502 | ChEMBL_ID |
| DB08872 | DRUGBANK_ID |
| C493250 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7560 | IUPHAR_LIGAND_ID |
| 8611 | INN_ID |
| 75OCL1SPBQ | UNII |
| 9883933 | PUBCHEM_CID |
| 1095698 | RXNORM |
| 180816 | MMSL |
| 27821 | MMSL |
| 4770 | MMSL |
| 60712 | MMSL |
| d03182 | MMSL |
| 004415 | NDDF |
| 013726 | NDDF |
| 108402001 | SNOMEDCT_US |
| 386845007 | SNOMEDCT_US |
| 703122000 | SNOMEDCT_US |
| C0060926 | UMLSCUI |
| DB00996 | DRUGBANK_ID |
| 3446 | PUBCHEM_CID |
| 5094 | INN_ID |
| D000077206 | MESH_DESCRIPTOR_UI |
| CHEBI:42797 | CHEBI |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Horizant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53451-0101 | TABLET, EXTENDED RELEASE | 600 mg | ORAL | NDA | 35 sections |
| Horizant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53451-0103 | TABLET, EXTENDED RELEASE | 300 mg | ORAL | NDA | 35 sections |